The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial

被引:8
|
作者
Heimburger, Sebastian M. N. [1 ,2 ,3 ]
Hoe, Bjorn [1 ,4 ]
Nielsen, Chris N. [1 ]
Bergmann, Natasha C. [1 ]
Hartmann, Bolette [3 ,5 ]
Holst, Jens J. [3 ,5 ]
Vilsboll, Tina [1 ,2 ,4 ]
Dejgaard, Thomas F. [1 ,2 ]
Christensen, Mikkel B. [1 ,4 ,6 ,7 ]
Knop, Filip K. [1 ,2 ,3 ,4 ]
机构
[1] Univ Copenhagen, Gentofte Hosp, Ctr Clin Metab Res, Hellerup, Denmark
[2] Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[3] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark
[4] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark
[5] Univ Copenhagen, Fac Hlth & Med Sci, Dept Biomed Sci, Copenhagen, Denmark
[6] Univ Copenhagen, Bispebjerg Hosp, Dept Clin Pharmacol, Copenhagen, Denmark
[7] Univ Copenhagen, Bispebjerg Hosp, Copenhagen Ctr Translat Res, Copenhagen, Denmark
关键词
Adipose tissue; Continuous glucose monitoring; GIP; Glucose-dependent insulinotropic polypeptide; Glycaemic control; Glycaemic time in range; Hypoglycaemia; Hypoglycaemic events; Insulin resistance; Insulin sensitivity; RECEPTOR AGONIST; GLUCAGON; HYPOGLYCEMIA; RESPONSES;
D O I
10.1007/s00125-021-05547-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis Type 1 diabetes is characterised by reduced glucagon response to hypoglycaemia, increasing the risk of insulin treatment-associated hypoglycaemia known to hamper glycaemic control. We previously reported a glucagonotropic effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) during insulin-induced hypoglycaemia in individuals with type 1 diabetes. Here we investigate the effect of a 6-day s.c. GIP infusion on time in glycaemic range as assessed by continuous glucose monitoring (CGM) in individuals with type 1 diabetes. Methods In a randomised, placebo-controlled, double-blind crossover study, time in glycaemic range (assessed by double-blinded CGM) was evaluated in 20 men with type 1 diabetes (18-75 years, stable insulin treatment >= 3 months, diabetes duration 2-15 years, fasting plasma C-peptide below 200 pmol/l, BMI 20-27 kg/m(2), HbA(1c) <69 mmol/mol [8.5%]) during two x 6 days of continuous s.c. GIP (6 pmol kg(-1) min(-1)) and placebo (saline [154 mmol/l NaCl]) infusion, respectively, with an interposed 7-day washout period. The primary outcome was glycaemic time below range, time in range and time above range. Results There were no significant differences in time below range (<3.9 mmol/l, p = 0.53) or above range (>10 mmol/l, p = 0.32) during night-time or daytime, in mean glucose, or in hypoglycaemic events as assessed by CGM. GIP altered neither self-reported hypoglycaemia nor safety measures. Compared with placebo, GIP significantly increased time in tight range (3.9-7.8 mmol/l) during daytime (06:00-23:59 hours) by [mean +/- SEM] 11.2 +/- 5.1% [95% CI 0.41, 21.9] (p = 0.02). Conclusions/interpretation Six-day s.c. GIP infusion in men with type 1 diabetes did not procure convincing effect on overall time in range, but increased time in tight glycaemic range during daytime by similar to 2 h per day.
引用
收藏
页码:2425 / 2431
页数:7
相关论文
共 50 条
  • [1] The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial
    Sebastian M. N. Heimbürger
    Bjørn Hoe
    Chris N. Nielsen
    Natasha C. Bergmann
    Bolette Hartmann
    Jens J. Holst
    Tina Vilsbøll
    Thomas F. Dejgaard
    Mikkel B. Christensen
    Filip K. Knop
    Diabetologia, 2021, 64 : 2425 - 2431
  • [2] Glucose-dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double-blind, placebo-controlled, crossover clinical trial
    Heimburger, Sebastian M. N.
    Nielsen, Chris N.
    Calanna, Salvatore
    Holst, Jens J.
    Vilsboll, Tina
    Knop, Filip K.
    Christensen, Mikkel B.
    DIABETES OBESITY & METABOLISM, 2022, 24 (01): : 142 - 147
  • [3] The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial
    Laurence Lion-François
    François Gueyffier
    Catherine Mercier
    Daniel Gérard
    Vania Herbillon
    Isabelle Kemlin
    Diana Rodriguez
    Tiphanie Ginhoux
    Emeline Peyric
    Virginie Coutinho
    Valentine Bréant
    Vincent des Portes
    Stéphane Pinson
    Patrick Combemale
    Behrouz Kassaï
    Orphanet Journal of Rare Diseases, 9
  • [4] The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial
    Lion-Francois, Laurence
    Gueyffier, Francois
    Mercier, Catherine
    Gerard, Daniel
    Herbillon, Vania
    Kemlin, Isabelle
    Rodriguez, Diana
    Ginhoux, Tiphanie
    Peyric, Emeline
    Coutinho, Virginie
    Breant, Valentine
    des Portes, Vincent
    Pinson, Stephane
    Combemale, Patrick
    Kassai, Behrouz
    ORPHANET JOURNAL OF RARE DISEASES, 2014, 9 : 142
  • [5] Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
    Bailey, Clifford J.
    Gross, Jorge L.
    Pieters, Anne
    Bastien, Arnaud
    List, James F.
    LANCET, 2010, 375 (9733): : 2223 - 2233
  • [6] The effect of zinc supplementation on glucose homeostasis: a randomised double-blind placebo-controlled trial
    Attia, John R.
    Holliday, Elizabeth
    Weaver, Natasha
    Peel, Roseanne
    Fleming, Kerry C.
    Hure, Alexis
    Wiggers, John
    McEvoy, Mark
    Searles, Andrew
    Reeves, Penny
    Ranasinghe, Priyanga
    Jayawardena, Ranil
    Samman, Samir
    Luu, Judy
    Rissel, Chris
    Acharya, Shamasunder
    ACTA DIABETOLOGICA, 2022, 59 (07) : 965 - 975
  • [7] The effect of zinc supplementation on glucose homeostasis: a randomised double-blind placebo-controlled trial
    John R. Attia
    Elizabeth Holliday
    Natasha Weaver
    Roseanne Peel
    Kerry C. Fleming
    Alexis Hure
    John Wiggers
    Mark McEvoy
    Andrew Searles
    Penny Reeves
    Priyanga Ranasinghe
    Ranil Jayawardena
    Samir Samman
    Judy Luu
    Chris Rissel
    Shamasunder Acharya
    Acta Diabetologica, 2022, 59 : 965 - 975
  • [8] Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study
    Xie, Cong
    Iroga, Peter
    Bound, Michelle J.
    Grivell, Jacqueline
    Huang, Weikun
    Jones, Karen L.
    Horowitz, Michael
    Rayner, Christopher K.
    Wu, Tongzhi
    DIABETOLOGIA, 2024, 67 (07) : 1260 - 1270
  • [9] Effect of liquid ubiquinol supplementation on glucose, lipids and antioxidant capacity in type 2 diabetes patients: a double-blind, randomised, placebo-controlled trial
    Yen, Chi-Hua
    Chu, Ying-Ju
    Lee, Bor-Jen
    Lin, Yi-Chin
    Lin, Ping-Ting
    BRITISH JOURNAL OF NUTRITION, 2018, 120 (01) : 57 - 63
  • [10] Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial
    Petrie, John R.
    Chaturvedi, Nishi
    Ford, Ian
    Brouwers, Martijn C. G. J.
    Greenlaw, Nicola
    Tillin, Therese
    Hramiak, Irene
    Hughes, Alun D.
    Jenkins, Alicia J.
    Klein, Barbara E. K.
    Klein, Ronald
    Ooi, Teik C.
    Rossing, Peter
    Stehouwer, Coen D. A.
    Sattar, Naveed
    Colhoun, Helen M.
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (08): : 597 - 609